• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Bank on the fact that CDHC is here to stay

Article

As healthcare costs continue to spiral, the search for solutions is reaching a frantic pace. My experiences over the years have led me to believe that while Consumer- Directed Healthcare (CDHC) has entered the mainstream lexicon, it is far from understood.

As healthcare costs continue to spiral, the search for solutions is reaching a frantic pace. My experiences over the years have led me to believe that while Consumer- Directed Healthcare (CDHC) has entered the mainstream lexicon, it is far from understood.

The purpose of this and future columns, which will appear in MANAGED HEALTHCARE EXECUTIVE, is to bring healthcare executives up to speed on what CDHC is and isn't, what it can and can't achieve, and why you need to know more about it.

Some facts about the growth of CDHC:

The first thing healthcare executives need to do when they research CDHC options is to think of it as a completely new business model that focuses on the consumer. Thinking of HSAs, health reimbursement accounts (HRAs), flexible spending accounts (FSAs) and other high-deductible health plans in the same terms as HMOs and PPOs will only lead to frustration and, ultimately, failure. Consumer-driven health requires business transformation, shifting the focus to respond to and serve a member's needs as a consumer.

Further, while healthcare costs are a primary driver for the push to CDHC, money is not the answer. No financial incentive, attractive as it might be, will effectively teach people how to use their healthcare spending accounts. Only patience and education can accomplish that, which means easier-to-understand tools will need to be developed and made widely available.

The connection with the member starts before the point of sale. Health plans will need tools for enrollment that help the members understand the decisions they are making. Cost calculators and tools that explain the various cash accounts will be critical factors for success.

Things to consider:

New, member-centric, Web-based technologies will be key to success. Consumers are not incompetent, just inexperienced. Once they understand their role, members will:

Achieving any one of the above would constitute a significant improvement in the healthcare system; taken as a whole, they amount to an industry transformation.

In future installments, I'll outline key success factors and what steps health plans can take today to be prepared for the future of CDHC.

Kathy McAleer, a veteran in the rapidly growing field of Consumer-Directed Healthcare, is vice president of operations for QCSI's MyHealthBank product line.

Related Videos
Video 3 - "In-Office Procedures, Over-the-Counter Options, Treatment Delays, and Costs"
Video 6 - "Safety Analysis and Interpreting Results from MAJIC-PV"
Video 5 - "Key Findings from MAJIC-PV"
Video 2 - "Traditional Treatment of Demodex Blepharitis, FDA approval, and Lotilaner Ophthalmic Solution, 0.25%"
Gabriela Hobbs, MD, an expert on polycythemia vera
Gabriela Hobbs, MD, and Timothy Mok, PharmD, BCPS, BCOP
Video 1 - "Demodex Blepharitis: Prevalence, Symptoms, Quality of Life Impact, and Diagnosis"
Video 2 - "The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance"
Video 1 - "Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera"
Related Content
© 2024 MJH Life Sciences

All rights reserved.